|
|
|
|
   |
 |
► Home ﹥Investor
|
As of 2008, PharmaEssentia has issued 108.25 M shares with the booked capital of NT$ 1,082.5 million. We are currently under the Round C and aim at raising NT$ 461 million for capital. All of the increased capital will be used for clinical trails of P1101(PEG-IFN-α-2b), pre-clinical trial of PEG-IFN-β and PEG-EPO, research instrument investment, and the operating expense for 2009.
Round A: NT$501 millions. – October, 2003
Round B: NT$581.5 millions. –May, 2005
Round C: processing.
Main Investors:
Funding team & others led by Dr. Ko Chung Lin
National Development Fund, Executive Yuan
Yao-Hua Glass Co., Ltd.
Synmosa Biopharma
Genovate Biotechnology
PhytoHealth
CTCI Corporation
Global Strategic Investment Fund
Investor Contract:
Peggy Lee
Phone: 886-2-2655-7688
Fax: 886-2-2655-7626
Email: info@pharmaessentia.com
|
 Copyright © 2008 PharmaEssentia Corporation All Rights Reserved. |
|